Brokerages predict that Hill-Rom Holdings, Inc. (NYSE:HRC) will report sales of $656.40 million for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Hill-Rom’s earnings, with estimates ranging from $653.20 million to $659.10 million. Hill-Rom reported sales of $637.40 million in the same quarter last year, which indicates a positive year-over-year growth rate of 3%. The firm is scheduled to announce its next quarterly earnings report on Friday, January 26th.

On average, analysts expect that Hill-Rom will report full year sales of $656.40 million for the current year, with estimates ranging from $2.83 billion to $2.86 billion. For the next year, analysts forecast that the firm will post sales of $2.94 billion per share, with estimates ranging from $2.90 billion to $2.98 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Hill-Rom.

Hill-Rom (NYSE:HRC) last announced its quarterly earnings results on Friday, November 3rd. The medical technology company reported $1.32 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.27 by $0.05. The company had revenue of $738.30 million for the quarter, compared to analyst estimates of $731.10 million. Hill-Rom had a net margin of 4.87% and a return on equity of 20.27%. The firm’s revenue was up 4.6% on a year-over-year basis. During the same period in the prior year, the firm posted $1.18 earnings per share.

A number of equities analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of Hill-Rom from a “sell” rating to a “hold” rating in a research report on Tuesday, October 3rd. ValuEngine lowered shares of Hill-Rom from a “buy” rating to a “hold” rating in a research report on Saturday, November 4th. Stifel Nicolaus raised their target price on shares of Hill-Rom from $84.00 to $85.00 and gave the stock a “buy” rating in a research report on Monday, November 6th. Barclays increased their price target on Hill-Rom from $86.00 to $90.00 and gave the stock an “overweight” rating in a report on Monday, November 6th. Finally, Needham & Company LLC decreased their price target on Hill-Rom from $93.00 to $90.00 and set a “buy” rating for the company in a report on Monday, November 6th. Five research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $89.57.

In related news, CEO John J. Greisch sold 100,000 shares of the stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $82.82, for a total transaction of $8,282,000.00. Following the completion of the sale, the chief executive officer now directly owns 230,851 shares of the company’s stock, valued at $19,119,079.82. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 2.20% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. US Bancorp DE lifted its holdings in Hill-Rom by 4.9% in the second quarter. US Bancorp DE now owns 4,524 shares of the medical technology company’s stock valued at $360,000 after acquiring an additional 212 shares during the period. Russell Investments Group Ltd. lifted its holdings in Hill-Rom by 37.5% in the second quarter. Russell Investments Group Ltd. now owns 86,003 shares of the medical technology company’s stock valued at $6,847,000 after acquiring an additional 23,435 shares during the period. Great West Life Assurance Co. Can lifted its holdings in Hill-Rom by 2.1% in the second quarter. Great West Life Assurance Co. Can now owns 37,354 shares of the medical technology company’s stock valued at $2,972,000 after acquiring an additional 766 shares during the period. IFP Advisors Inc lifted its holdings in Hill-Rom by 3.0% in the second quarter. IFP Advisors Inc now owns 4,607 shares of the medical technology company’s stock valued at $367,000 after acquiring an additional 135 shares during the period. Finally, Canada Pension Plan Investment Board lifted its holdings in Hill-Rom by 42.7% in the second quarter. Canada Pension Plan Investment Board now owns 16,700 shares of the medical technology company’s stock valued at $1,329,000 after acquiring an additional 5,000 shares during the period. 82.35% of the stock is owned by hedge funds and other institutional investors.

Shares of Hill-Rom (NYSE HRC) traded up $0.74 on Thursday, hitting $83.33. 385,900 shares of the stock were exchanged, compared to its average volume of 501,260. The company has a current ratio of 1.77, a quick ratio of 1.34 and a debt-to-equity ratio of 1.55. The stock has a market capitalization of $5,480.00, a price-to-earnings ratio of 21.40, a PEG ratio of 1.76 and a beta of 1.19. Hill-Rom has a twelve month low of $54.59 and a twelve month high of $85.25.

The business also recently declared a quarterly dividend, which will be paid on Friday, December 29th. Investors of record on Friday, December 15th will be issued a dividend of $0.18 per share. This represents a $0.72 annualized dividend and a dividend yield of 0.86%. The ex-dividend date of this dividend is Thursday, December 14th. Hill-Rom’s dividend payout ratio is presently 36.18%.

WARNING: This piece was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2017/12/14/656-40-million-in-sales-expected-for-hill-rom-holdings-inc-hrc-this-quarter.html.

Hill-Rom Company Profile

Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.

Get a free copy of the Zacks research report on Hill-Rom (HRC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Hill-Rom (NYSE:HRC)

Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.